Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers Did you know that your browser is out of date? To get the best experience …

Objectives: This study was designed to identify all randomized clinical trial data evaluating
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for the prevention …

Large clinical trials have demonstrated that angiotensin-converting-enzyme (ACE) inhibitors
are associated with beneficial outcomes in patients with arterial hypertension, heart failure …

Atrial fibrillation (AF) is the most frequent sustained arrhythmia found in clinical practice. 1, 2
According to the Framingham Heart Study, AF has a prevalence of 4% in the adult …

The inhibition of the renin‐angiotensin system has demonstrated both experimental and
clinical effects in preventing atrial fibrillation. However, there is still uncertainty about the role …

BACKGROUND: Several studies have indicated that treatment with angiotensin converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers (ARBs) may reduce the …

We thank Professors Celik and Iyisoy for their comments on the Candesartan in the
Prevention of Relapsing Atrial Fibrillation (CAPRAF) study [1]. This was the first double blind …

Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical
practice, affecting approximately 250,000 Canadians and accounting for more than 120,000 …

Background: Controversy persists regarding the efficacy of angiotensin converting enzyme
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in the prevention of recurrent …

Review: Angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent
atrial fibrillation. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …